BIONTECH SE-ADR(NASDAQ:BNTX) stock Fundamental Analysis

Fundamental Rating

Taking everything into account, BNTX scores 4 out of 10 in our fundamental rating. BNTX was compared to 571 industry peers in the Biotechnology industry. While BNTX has a great health rating, its profitability is only average at the moment. BNTX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

BNTX had negative earnings in the past year.

In the past year BNTX had a positive cash flow from operations.

Of the past 5 years BNTX 4 years were profitable.

In multiple years BNTX reported negative operating cash flow during the last 5 years.

1.2 Ratios

The Return On Assets of BNTX (-2.08%) is better than 91.12% of its industry peers.

BNTX has a Return On Equity of -2.44%. This is amongst the best in the industry. BNTX outperforms 92.54% of its industry peers.

		Industry Rank	Sector Rank
ROA	-2.08%
ROE	-2.44%
ROIC	N/A

ROA(3y)36.53%

ROA(5y)17.56%

ROE(3y)46.06%

ROE(5y)20.59%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

In the last couple of years the Profit Margin of BNTX has grown nicely.

The Gross Margin of BNTX (87.71%) is better than 90.94% of its industry peers.

In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for BNTX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	87.71%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y98.55%

PM growth 5YN/A

GM growth 3Y-1.33%

GM growth 5Y-1.09%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.

BNTX has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, BNTX has more shares outstanding

BNTX has a worse debt/assets ratio than last year.

2.2 Solvency

BNTX has an Altman-Z score of 7.00. This indicates that BNTX is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of BNTX (7.00) is better than 82.59% of its industry peers.

The Debt to FCF ratio of BNTX is 0.25, which is an excellent value as it means it would take BNTX, only 0.25 years of fcf income to pay off all of its debts.

BNTX has a better Debt to FCF ratio (0.25) than 96.80% of its industry peers.

BNTX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.

BNTX's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. BNTX outperforms 42.10% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	0.25
Altman-Z	7

ROIC/WACCN/A

WACC6.78%

2.3 Liquidity

BNTX has a Current Ratio of 7.33. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 7.33, BNTX is doing good in the industry, outperforming 69.27% of the companies in the same industry.

BNTX has a Quick Ratio of 7.21. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 7.21, BNTX is in the better half of the industry, outperforming 68.38% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.33
Quick Ratio	7.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BNTX have decreased strongly by -117.52% in the last year.

BNTX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 279.64% yearly.

BNTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -54.07%.

BNTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 97.22% yearly.

EPS 1Y (TTM)-117.52%

EPS 3Y279.64%

EPS 5YN/A

EPS Q2Q%20.9%

Revenue 1Y (TTM)-54.07%

Revenue growth 3Y99.36%

Revenue growth 5Y97.22%

Sales Q2Q%39.04%

3.2 Future

Based on estimates for the next years, BNTX will show a very negative growth in Earnings Per Share. The EPS will decrease by -17.80% on average per year.

Based on estimates for the next years, BNTX will show a decrease in Revenue. The Revenue will decrease by -4.48% on average per year.

EPS Next Y-185.35%

EPS Next 2Y-70.23%

EPS Next 3Y-42.65%

EPS Next 5Y-17.8%

Revenue Next Year-38.23%

Revenue Next 2Y-22.56%

Revenue Next 3Y-15.73%

Revenue Next 5Y-4.48%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

BNTX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BNTX is cheaper than 95.20% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	28.42
EV/EBITDA	N/A

4.3 Compensation for Growth

BNTX's earnings are expected to decrease with -42.65% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-70.23%

EPS Next 3Y-42.65%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BNTX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIONTECH SE-ADR

NASDAQ:BNTX (2/21/2025, 12:35:58 PM)

120.04

+2.16 (+1.83%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-04 2024-11-04/bmo

Earnings (Next)N/A N/A

Inst Owners19.03%

Inst Owner Change15.23%

Ins Owners2.05%

Ins Owner ChangeN/A

Market Cap28.78B

Analysts79.26

Price Target141.97 (18.27%)

Short Float %2.99%

Short Ratio4.03

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)44.04%

Min EPS beat(2)-62.82%

Max EPS beat(2)150.91%

EPS beat(4)1

Avg EPS beat(4)11.69%

Min EPS beat(4)-62.82%

Max EPS beat(4)150.91%

EPS beat(8)5

Avg EPS beat(8)271.9%

EPS beat(12)8

Avg EPS beat(12)194.11%

EPS beat(16)12

Avg EPS beat(16)219.92%

Revenue beat(2)1

Avg Revenue beat(2)47.3%

Min Revenue beat(2)-13.02%

Max Revenue beat(2)107.62%

Revenue beat(4)1

Avg Revenue beat(4)4.24%

Min Revenue beat(4)-56.98%

Max Revenue beat(4)107.62%

Revenue beat(8)2

Avg Revenue beat(8)-8.54%

Revenue beat(12)5

Avg Revenue beat(12)4.91%

Revenue beat(16)9

Avg Revenue beat(16)15.52%

PT rev (1m)1.75%

PT rev (3m)5.13%

EPS NQ rev (1m)-34.64%

EPS NQ rev (3m)-71.52%

EPS NY rev (1m)-4.57%

EPS NY rev (3m)-7.88%

Revenue NQ rev (1m)4.02%

Revenue NQ rev (3m)-11.74%

Revenue NY rev (1m)0.41%

Revenue NY rev (3m)0.9%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	9.06
P/FCF	28.42
P/OCF	18.11
P/B	1.44
P/tB	1.54
EV/EBITDA	N/A

EPS(TTM)-2.05

EYN/A

EPS(NY)-3.59

Fwd EYN/A

FCF(TTM)4.22

FCFY3.52%

OCF(TTM)6.63

OCFY5.52%

SpS13.24

BVpS83.26

TBVpS77.83

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-2.08%
ROE	-2.44%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	87.71%
FCFM	31.9%

ROA(3y)36.53%

ROA(5y)17.56%

ROE(3y)46.06%

ROE(5y)20.59%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)61.51%

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y98.55%

PM growth 5YN/A

GM growth 3Y-1.33%

GM growth 5Y-1.09%

F-Score2

Asset Turnover0.14

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	0.25
Debt/EBITDA	N/A
Cap/Depr	261.47%
Cap/Sales	18.15%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.33
Quick Ratio	7.21
Altman-Z	7

F-Score2

WACC6.78%

ROIC/WACCN/A

Cap/Depr(3y)295.05%

Cap/Depr(5y)262.38%

Cap/Sales(3y)7.13%

Cap/Sales(5y)20.83%

Profit Quality(3y)216.26%

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-117.52%

EPS 3Y279.64%

EPS 5YN/A

EPS Q2Q%20.9%

EPS Next Y-185.35%

EPS Next 2Y-70.23%

EPS Next 3Y-42.65%

EPS Next 5Y-17.8%

Revenue 1Y (TTM)-54.07%

Revenue growth 3Y99.36%

Revenue growth 5Y97.22%

Sales Q2Q%39.04%

Revenue Next Year-38.23%

Revenue Next 2Y-22.56%

Revenue Next 3Y-15.73%

Revenue Next 5Y-4.48%

EBIT growth 1Y-120.59%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-207.46%

EBIT Next 3Y-45.09%

EBIT Next 5Y-6.64%

FCF growth 1Y-92.1%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-87.88%

OCF growth 3YN/A

OCF growth 5YN/A

BIONTECH SE-ADR (BNTX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens